Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
APLS
Stock Latest News
The Fly
Apellis price target raised to $50 from $47 at Baird
1d ago
APLS
Premium
The Fly
Apellis price target raised to $24 from $23 at BofA
3d ago
APLS
Premium
Ratings
Apellis Pharmaceuticals: Strong Market Position and Growth Potential Justify Buy Rating
5d ago
APLS
Premium
Ratings
Apellis Pharmaceuticals: Sustained Growth Potential and Market Resilience Justify Buy Rating
9d ago
APLS
Premium
The Fly
Apellis price target raised to $26 from $25 at Morgan Stanley
17d ago
APLS
Premium
Ratings
Cautious Optimism: Apellis Pharmaceuticals’ Strategic Moves and Market Uncertainties Justify Hold Rating
18d ago
APLS
Premium
Ratings
Strategic Financial Maneuvers and Market Opportunities Drive Buy Rating for Apellis Pharmaceuticals
18d ago
APLS
Premium
Company Announcements
Apellis Pharmaceuticals Secures $275M Royalty Buy-Down Deal
18d ago
8K
APLS
Premium
The Fly
Apellis to receive up to $300M from royalty purchase agreement with Sobi
18d ago
APLS
Premium
Company Announcements
Apellis Pharmaceuticals’ Phase 3 Study Update: Long-Term Efficacy of Pegcetacoplan
23d ago
APLS
Premium
Company Announcements
Apellis Pharmaceuticals’ Phase 3 Study on Pegcetacoplan: A Potential Game-Changer in AMD Treatment
25d ago
APLS
Premium
The Fly
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study
1M ago
APLS
Premium
Company Announcements
Apellis Pharmaceuticals Holds Annual Stockholders Meeting
1M ago
8K
APLS
Premium
The Fly
Apellis price target raised to $29 from $26 at Wells Fargo
2M ago
APLS
Premium
The Fly
Apellis price target raised to $29 from $26 at Wells Fargo
2M ago
APLS
Premium
Ratings
Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability
2M ago
APLS
Premium
The Fly
Apellis price target lowered to $41 from $49 at Citi
2M ago
APLS
Premium
The Fly
Apellis price target lowered to $20 from $30 at Mizuho
2M ago
APLS
Premium
Ratings
Buy Recommendation for Apellis Pharmaceuticals Driven by Syfovre’s Market Potential and Strategic Expansion
2M ago
APLS
Premium
The Fly
Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
2M ago
ROK
AFRM
Premium
The Fly
Apellis downgraded to Neutral from Buy at BofA
2M ago
APLS
Premium
The Fly
Apellis downgraded to Outperform from Strong Buy at Raymond James
2M ago
APLS
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
